119 related articles for article (PubMed ID: 20430182)
1. Preemptive therapy in adult liver transplant recipients in CMV-endemic area.
Kim JM; Kim SJ; Joh JW; Shin M; Kim EY; Moon JI; Jung GO; Choi GS; Kwon CH; Lee SK
Transplant Proc; 2010 Apr; 42(3):825-9. PubMed ID: 20430182
[TBL] [Abstract][Full Text] [Related]
2. The risk factors for cytomegalovirus syndrome and tissue-invasive cytomegalovirus disease in liver transplant recipients who have cytomegalovirus antigenemia.
Kim JM; Kim SJ; Joh JW; Shin M; Moon JI; Jung GO; Choi GS; Kwon CH; Lee SK
Transplant Proc; 2010 Apr; 42(3):890-4. PubMed ID: 20430198
[TBL] [Abstract][Full Text] [Related]
3. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
4. The effect of cytomegalovirus antigenemia titer on the efficacy of preemptive therapy for the prevention of cytomegalovirus disease after kidney transplantation.
Jung GO; Kim SJ; Choi GS; Moon JI; Kim JM; Sin MJ; Kim EY; Kwon CH; Joh JW; Lee SK
Transplant Proc; 2010 Apr; 42(3):804-10. PubMed ID: 20430177
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience.
Perrella A; Esposito C; Ioia G; Campanella L; Taglialatela D; Cuomo O
Transplant Proc; 2010 May; 42(4):1226-8. PubMed ID: 20534267
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
[TBL] [Abstract][Full Text] [Related]
7. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus reactivation and preemptive therapy after liver transplant.
Davoudi S; Kasraianfard A; Ahmadinejad Z; Najafi A; Salimi J; Makarem J; Sohrabpour AA; Jafarian A
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():72-5. PubMed ID: 24635797
[TBL] [Abstract][Full Text] [Related]
9. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
[TBL] [Abstract][Full Text] [Related]
10. A short-term preemptive treatment for cytomegalovirus infection in seropositive patients after liver transplantation.
Dahiya D; Lee CF; Chan KM; Wu TJ; Chou HS; Cheng SS; Lee WC
J Hepatobiliary Pancreat Sci; 2011 Jan; 18(1):32-8. PubMed ID: 20499109
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy preemptive therapy with ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients].
López-Medrano F; Lumbreras C; Otero JR; González-Alegre MT; San Juan R; Folgueira D; Lizasoaín M; Loinaz C; Moreno E; Aguado JM
Med Clin (Barc); 2004 Jan; 122(2):41-5. PubMed ID: 14733853
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients.
Kusne S; Grossi P; Irish W; St George K; Rinaldo C; Rakela J; Fung J
Transplantation; 1999 Oct; 68(8):1125-31. PubMed ID: 10551640
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus infection renal transplant recipients: risk factors and outcome.
Kanter J; Pallardó L; Gavela E; Escudero V; Beltrán S; Morales A; Avila A; Crespo JF
Transplant Proc; 2009; 41(6):2156-8. PubMed ID: 19715860
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
[TBL] [Abstract][Full Text] [Related]
15. Early and delayed onset cytomegalovirus infection of liver transplant recipients in endemic areas.
Kim JM; Kim SJ; Joh JW; Kwon CH; Shin M; Kim EY; Moon JI; Jung GO; Choi GS; Lee SK
Transplant Proc; 2010 Apr; 42(3):884-9. PubMed ID: 20430197
[TBL] [Abstract][Full Text] [Related]
16. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
De Santo LS; Romano G; Mastroianni C; Roberta C; Della Corte A; Amarelli C; Maiello C; Giannolo B; Marra C; Ragone E; Grimaldi M; Utili R; Scardone M; Cotrufo M
Transplant Proc; 2005; 37(6):2684-7. PubMed ID: 16182784
[TBL] [Abstract][Full Text] [Related]
17. Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies.
Ozaki KS; Pestana JO; Granato CF; Pacheco-Silva A; Camargo LF
Transpl Infect Dis; 2004 Jun; 6(2):63-8. PubMed ID: 15522106
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients.
Casillo R; Grimaldi M; Ragone E; Maiello C; Marra C; De Santo L; Amarelli C; Romano G; Della Corte A; Portella G; Tripodi MF; Fortunato R; Cotrufo M; Utili R
Transplant Proc; 2004 Apr; 36(3):651-3. PubMed ID: 15110622
[TBL] [Abstract][Full Text] [Related]
19. Preemptive therapy in CMV-antigen positive patients after liver transplantation--a prospective trial.
Rayes N; Oettle H; Schmidt CA; Lohmann R; Steinmüller T; Bechstein WO; Neuhaus P
Ann Transplant; 1999; 4(2):12-7. PubMed ID: 10850585
[TBL] [Abstract][Full Text] [Related]
20. The effects of preemptive therapy using a very low threshold of pp65 antigenemia to prevent cytomegalovirus disease in kidney transplant recipients: a single-center experience.
Saracino A; Colucci R; Latorraca A; Muscaridola N; Procida C; Di Noia I; Santospirito VE; Santarsia G
Transplant Proc; 2013; 45(1):182-4. PubMed ID: 23375295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
